Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Sarah Cannon Research Institute
Collaborators:
Bayer
Bristol-Myers Squibb
Information provided by (Responsible Party):
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT00825734
First received: January 19, 2009
Last updated: December 12, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | March 2013 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |